Dimerix Ltd
ASX:DXB

Watchlist Manager
Dimerix Ltd Logo
Dimerix Ltd
ASX:DXB
Watchlist
Price: 0.53 AUD 1.92% Market Closed
Market Cap: 318.2m AUD

Operating Margin

-524.3%
Current
Improving
by 15 680.1%
vs 3-y average of -16 204.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-524.3%
=
Operating Income
AU$-31m
/
Revenue
AU$5.9m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-524.3%
=
Operating Income
AU$-31m
/
Revenue
AU$5.9m

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Dimerix Ltd
ASX:DXB
317.2m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.6B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.9B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in Australia
Percentile
30th
Based on 3 951 companies
30th percentile
-524.3%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Dimerix Ltd
Glance View

Market Cap
318.2m AUD
Industry
Biotechnology

Dimerix Ltd. engages in the investment in research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is engaged in the development of new therapies in areas with unmet medical need. The firm is developing four product indications: Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19, diabetic kidney disease, and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD), as well as the its Receptor-HIT assay technology. The Company’s pipeline products include DMX-200, DMX-700 and DMX-XXX. DMX-200, which is developed for FSGS, COVID-19 pneumonia patient in ICU and respiratory complications in COVID-19 patients is under Phase III clinical trial. DMX-200, which is developed for diabetic kidney disease is under Phase II clinical trial. DMX-700, which is developed for COPD is under Phase I clinical trial. DMX-XXX is under Phase I clinical trial.

DXB Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-524.3%
=
Operating Income
AU$-31m
/
Revenue
AU$5.9m
What is Dimerix Ltd's current Operating Margin?

The current Operating Margin for Dimerix Ltd is -524.3%, which is above its 3-year median of -16 204.4%.

How has Operating Margin changed over time?

Over the last 3 years, Dimerix Ltd’s Operating Margin has increased from -435 162.5% to -524.3%. During this period, it reached a low of -435 162.5% on May 30, 2022 and a high of -524.3% on Jul 30, 2025.

Back to Top